Effects of Rofecoxib or Naproxen vs Placebo on Alzheimer Disease Progression: A Randomized Controlled Trial

JAMA

Volumn 289, Issue 21, 2003, Pages 2819-2826

  Aisen, Paul S ^a   Schafer, Kimberly A ^b   Grundman, Michael ^b   Pfeiffer, Eric ^c   Sano, Mary ^d   Davis, Kenneth L ^e   Farlow, Martin R ^f   Jin, Shelia ^b   Thomas, Ronald G ^g   Thal, Leon J ^b  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d Univ of South Florida Coll of Med ^*  (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; ROFECOXIB; CYCLOOXYGENASE 2; ISOENZYME; LACTONE; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN; SULFONE;

ADULT; AGED; ALZHEIMER DISEASE; AMBULATORY CARE; ARTICLE; BLEEDING; CLINICAL TRIAL; COGNITION; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; EPIDEMIOLOGICAL DATA; FATIGUE; FEMALE; GASTROINTESTINAL SYMPTOM; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; INTESTINE PERFORATION; KIDNEY FAILURE; LABORATORY DIAGNOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; MYALGIA; NERVE CELL LESION; OUTCOMES RESEARCH; PATIENT REFERRAL; PEPTIC ULCER; POPULATION RESEARCH; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RISK ASSESSMENT; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; STROKE; SUBDURAL HEMATOMA; TRANSIENT ISCHEMIC ATTACK; VERTIGO; XEROSTOMIA; DAILY LIFE ACTIVITY; DRUG ANTAGONISM; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; AGED; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISOENZYMES; LACTONES; MALE; MEMBRANE PROTEINS; NAPROXEN; NEUROPSYCHOLOGICAL TESTS; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; REGRESSION ANALYSIS; SULFONES; TREATMENT OUTCOME;

EID: 0037638809     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.21.2819     Document Type: Article

References (29)

1. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging. 2000; 21:383-421.
2. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
3. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 1993;43:1609-1611.
4. Scharf S, Mander A, Ugoni A, Vajda F, Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 1999;53:197-201.
5. Aisen PS, Davis KL, Berg JD, et al. A randomized controlled trial of prednisone in Alzheimer's disease: Alzheimer's Disease Cooperative Study. Neurology. 2000;54:588-593.
6. Van Gool WA, Weinstein HC, Scheltens PK, Walstra GJ. Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet. 2001;358:455-460.
7. in t' Veld BA, Ruitenberg A, Hofman A, et al. Non-steroidal and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
8. Lim GP, Yang F, Chu T, et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci. 2000;20: 5709-5714.
9. Lim GP, Yang F, Chu T, et al. Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol Aging. 2001;22:983-991.
10. Pasinetti GM, Aisen PS. Cyclooxygenase-2 expression is increased in frontal cortex of Alzheimer's disease brain. Neuroscience. 1998;87:319-324.
11. Bazan NG, Lukiw WJ. Cyclooxygenase-2 and presenilin-1 gene expression induced by interleukin-1 beta and amyloid beta 42 peptide is potentiated by hypoxia in primary human neural cells. J Biol Chem. 2002; 277:30359-30367.
12. Andreasson KI, Savonenko A, Vidensky S, et al. Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J Neurosci. 2001;21:8198-8209.
13. Xiang Z, Ho L, Valdellon J, et al. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol Aging. 2002;23:327-334.
14. Ho L, Purohit D, Haroutunian V, et al. Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer disease. Arch Neurol. 2001;58:487-492.
15. McGeer PL, McGeer EG. Inflammation, autotoxicity and Alzheimer disease. Neurobiol Aging. 2001; 22:799-809.
16. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group. Neurology. 1984;34:939-944.
17. Folstein M, Folstein S, Mchugh P. The Mini-Mental State Examination. J Psychiatr Res. 1975;12: 189-198.
18. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry. 1984;141: 1356-1364.
19. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993; 43:2412-2414.
20. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1997;11(suppl 2):S33-S39.
21. Cummings J. The neuropsychiatric inventory: assessing psychopathology in dementia patients. Neurology. 1997;48 (suppl 6):S10-S16.
22. Logsdon RG, Gibbons LE, McCurry SM, Teri L. Quality of life in Alzheimer's disease: patient and caregiver reports. J Mental Health Aging. 1999;5:21-32.
23. Zeger S, Liang K-Y. Longitudinal data analysis fordiscrete and continuous data. Biometrics. 1986; 42:121-130.
24. Weggen S, Eriksen JL, Das P, et al. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001;414:212-216.
25. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000; 342:1946-1952.
26. Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer's disease and duration of NSAID use. Neurology. 1997;48:626-632.
27. in't Veld BA, Ruitenberg A, Hofman A, et al. Non-steroidal antiinflammatory drugs and the risk of Alzheimer's disease. N Engl J Med. 2001;345:1515-1521.
28. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J. Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology. 1995;45:51-55.
29. Prevention of Alzheimer's and cognitive decline: grant 7U01AG015477-03. Available at: http://crisp .cit.nih.gov/crisp/Crisp_Query.Generate_Screen. Accessed February 2003.